Excagol medtech is developing advanced AI-driven imaging solutions that redefine non-invasive diagnostics for vascular health. Our innovative technologies enable medical professionals to visualize and analyze vascular structures with exceptional precision, improving diagnostic workflows and enhancing patient care.
Excagol’s Vision: We aspire to lead the future of AI-powered medical imaging by delivering innovative, non-invasive solutions that empower healthcare professionals to tackle complex diagnostic challenges with confidence. Our mission is to transform diagnostic accuracy and efficiency through advanced AI technologies, fostering better outcomes for patients and professionals.
As part of this commitment, we proudly introduce Proxinnovate—a comprehensive service that enhances the functionality and efficiency of our imaging solutions. Proxinnovate integrates advanced features and intelligent capabilities, making our software tools more intuitive and impactful for diverse diagnostic needs.
With our innovative AI solutions and the benefits of Proxinnovate, excagol medtech is dedicated to improve medical imaging and driving progress in healthcare innovation. Together, we are shaping a future where technology and care converge for the ultimate benefit of patients and professionals.
Oktober 2025 – Excagol Medtech freut sich über einen wichtigen wissenschaftlichen Fortschritt: In Kooperation mit der HAW Hamburg wurde eine wissenschaftliche Arbeit zur Entwicklung und Validierung eines KI-Moduls für die …
September 2024 – Wir haben das Tech Camp mit der Vision, Jugendliche zu unterstützen und ihnen einen Überblick über die technologische Entwicklung verschiedener Software- und Hardwareprodukte zu geben, erfolgreich in …
July 2024 – Exciting News 🚀 🤖 AI Labeling Software Our AI Labeling Software automates the detection and labeling of key features in ultrasound medical images. This powerful tool enhances …
Mai 2024 – Deutsch (English below) Eilon Mario Netzer hat excagol medtech während der Paneldiskussion als Teil des 2nd Track Digital Health am Universitätsklinikum Hamburg Eppendorf präsentiert. Die Veranstaltung war …
April 2024 – Excagol medtech in collaboration with the Hamburg School of Business Administration (HSBA) is thrilled to announce research findings that are set to transform the field of Venipuncture. …
March 2024 – In enger Kooperation mit den Gründern der herzmediziner Praxisgemeinschaft in Berlin Dr. med. Patrick Darb-Esfahani und Dr. med. Fabian Riediger geht excagol medtech einen weiteren Schritt auf …
Am 21.02.2024 startete excagol medtech unter der Leitung von PD Dr. med. Lars Müller eine Studie beim Dermatologikum in Hamburg unter dem Titel “Optimierung des KI-Modells: Datensammlung durch Ultraschallabbildung von …
February 2024 – Wir freuen uns über die Zusammenarbeit mit den Gründern der herzmediziner Praxisgemeinschaft in Berlin, Dr. med. Patrick Darb-Esfahani und Dr. med. Fabian Riediger. Diese Partnerschaft markiert einen …
January 2024 – excagol medtech had the privilege of participating in an insightful meeting organized by Life Science Nord at Fraunhofer IMTE yesterday in Lübeck, gaining valuable insights into developments …
November 2023 – We are proud to present the results of our latest scientific study, which focuses on the acceptance of our innovative electronic venipuncture device. This study is a …
November 2023 – We are thrilled to announce the successful completion of the scientific study in collaboration with the Hamburg University of Applied Sciences, Faculty of Engineering and Computer Science, Department …
October 2023 – In the world of startups and entrepreneurship, knowledge sharing and inspiration play huge roles in shaping the future of innovation. Recently, at the Machine Learning Engineering Days …
October 2023 – Exhilarating experience at the AI.STARTUP.HUB Hamburg acceleration program 🚀 Networking with other startups was invaluable, and our participation in workshops during the acceleration program with specialists provided us with …
September 2023 – We are thrilled to announce our participation in Machine Learning and Engineering Days 2023 – the premier conference where Machine Learning and Engineering drive innovation. Our dedicated …
July 2023 – Dr. med. Lars Müller, MBA, Leiter der gefäßchirurgischen Abteilung des Dermatologikums in Hamburg, sagt über excagol: “Ich habe excagol im Herbst 2022 kennengelernt und unterstütze sie seit Anfang …
June 2023 – We are thrilled to highlight the value and benefits we gained from the recent workshops focused on networking and talent development. At the AI.STARTUP.HUB, we recognize the …
May 2023 – At excagol medtech, we are excited to be selected for the Health Innovation Port (HIP) program founded by Philips. This incredible opportunity propels us towards a future …
May 2023 – We are thrilled to announce that excagol medtech has been selected to participate in the prestigious AI Startups Hub Accelerator Program in Hamburg! This incredible opportunity sets …
April 2023 – The excagol medtech team is pleased to present its cooperation with Youkey Germany GmbH, which has been in place since 2022. Excagol medtech is supported by Wilfried …
March 2023 – Collaboration with Priv.-Doz. Dr. med. Lars Müller and Mr. Saher Tatour – Newsletter sixth release – As a company dedicated to developing innovative technologies to optimise vein …
Februar 2023 – Vor etwa zweieinhalb Jahren stellten wir erstmals das Startup Excagol vor, das ein Gerät erfunden hat, welches dabei hilft, bei der Blutabnahme die Vene zu treffen. Bekanntlich dauern …
February 2023 – Newsletter fifth release – Operational test of the semi-automated venipuncture automate
December 2022 – Newsletter third release – Development of a prototype for a semi-automated venipuncture automate
November 2022 – Newsletter second release – Acceptance of the Electronic Venipuncture Automate
October 2022 – Subscribe to our Newsletter ! We are able to respond to any messages sent to newsletter@excagol-medtech.com
The R&D team at excagol just achieved a new development stage of image processing analysis which has been successfully tested. Further product development in the process 🚀
